moxetumomab pasudotox (Lumoxiti)
Jump to navigation
Jump to search
Indications
- treatment of hairy cell leukemia in patients who have failed >=2 previous treatments
Adverse effects
Mechanism of action
- anti-CD22 monoclonal antibody
More general terms
References
- ↑ Ingram I. Lumoxiti OK'd for Hairy Cell Leukemia - FDA approval marks first anti-CD22 drug for treating the rare disease. MedPage Today. Sept. 13, 2018 https://www.medpagetoday.com/hematologyoncology/leukemia/75087
FDA News Release. September 13, 2018 FDA approves new kind of treatment for hairy cell leukemia. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm